Are Wall Street Analysts Predicting Medtronic Stock Will Climb or Sink?

Core Insights - Medtronic plc (MDT) has a market capitalization of approximately $132 billion and operates in various medical technology sectors, including cardiovascular, neuroscience, medical-surgical, and diabetes care, providing device-based therapies globally [1] Stock Performance - Over the past 52 weeks, MDT shares have increased by 13.5%, underperforming the S&P 500 Index, which gained 15.2%. However, on a year-to-date basis, MDT has outperformed the S&P 500, returning 7.3% compared to the index's 1.6% rise [2] - MDT shares have also outperformed the State Street Health Care Select Sector SPDR ETF (XLV), which returned 6.1% over the same period [3] Financial Performance - On November 18, 2025, MDT reported strong Q2 2026 results, with adjusted EPS of $1.36 and revenue of $8.96 billion, surpassing forecasts. The company experienced a 6.6% revenue growth, with a notable 71% growth in Cardiac Ablation Solutions, marking the strongest cardiovascular revenue growth in over a decade, excluding pandemic effects [5] - For the fiscal year ending in April 2026, analysts project MDT's adjusted EPS to grow by 2.7% year-over-year to $5.64. The company has consistently exceeded consensus estimates in the last four quarters [6] Analyst Ratings and Price Targets - Among 27 analysts covering MDT, the consensus rating is a "Moderate Buy," consisting of 11 "Strong Buy" ratings, one "Moderate Buy," and 15 "Holds" [6] - Evercore ISI raised its price target for MDT to $115 while maintaining an "Outperform" rating. The mean price target of $110.50 indicates a 7.5% premium to current price levels, while the highest price target of $125 suggests a potential upside of 21.6% [8]